KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) EBIT Margin (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed EBIT Margin for 16 consecutive years, with 38336.97% as the latest value for Q1 2025.

  • Quarterly EBIT Margin changed N/A to 38336.97% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 132871.32% through Dec 2025, down 8125440.0% year-over-year, with the annual reading at 132871.32% for FY2025, 8125440.0% down from the prior year.
  • EBIT Margin hit 38336.97% in Q1 2025 for Inovio Pharmaceuticals, down from 17410.77% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 390.61% in Q3 2022 to a low of 44876.83% in Q4 2022.
  • Historically, EBIT Margin has averaged 23434.95% across 5 years, with a median of 20553.16% in 2021.
  • Biggest YoY gain for EBIT Margin was 2016255bps in 2022; the steepest drop was -3230307bps in 2022.
  • Year by year, EBIT Margin stood at 12573.76% in 2021, then plummeted by -257bps to 44876.83% in 2022, then surged by 41bps to 26686.29% in 2023, then surged by 35bps to 17410.77% in 2024, then tumbled by -120bps to 38336.97% in 2025.
  • Business Quant data shows EBIT Margin for INO at 38336.97% in Q1 2025, 17410.77% in Q4 2024, and 32945.87% in Q2 2024.